These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 10843168

  • 41. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
    Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR.
    Endocr Pract; 2019 Nov; 25(11):1191-1232. PubMed ID: 31760824
    [Abstract] [Full Text] [Related]

  • 42. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
    Toogood AA, Shalet SM.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):131-6. PubMed ID: 9920073
    [Abstract] [Full Text] [Related]

  • 43. High-affinity growth hormone (GH)-binding protein (GHBP), body fat mass, and insulin-like growth factor-binding protein-3 predict the GHBP response to GH therapy in adult GH deficiency syndrome.
    Roelen CA, Koppeschaar HP, de Vries WR, Doerga ME, Snel YE, Bol E, Zelissen PM, Thijssen JH, Blankenstein MA.
    Metabolism; 1999 Mar; 48(3):314-8. PubMed ID: 10094106
    [Abstract] [Full Text] [Related]

  • 44. Elderly people with hypothalamic-pituitary disease and growth hormone deficiency: lipid profiles, body composition and quality of life compared with control subjects.
    Li Voon Chong JS, Benbow S, Foy P, Wallymahmed ME, Wile D, MacFarlane IA.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):551-9. PubMed ID: 11106915
    [Abstract] [Full Text] [Related]

  • 45. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency.
    Baum HB, Katznelson L, Sherman JC, Biller BM, Hayden DL, Schoenfeld DA, Cannistraro KE, Klibanski A.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3184-9. PubMed ID: 9745423
    [Abstract] [Full Text] [Related]

  • 46. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
    Herrmann BL, Berg C, Vogel E, Nowak T, Renzing-Koehler K, Mann K, Saller B.
    Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
    [Abstract] [Full Text] [Related]

  • 47. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL, Boquete HR, Stalldecker G, Giaccio AV, Sobrado PG.
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [Abstract] [Full Text] [Related]

  • 48. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency.
    Kawai N, Kanzaki S, Takano-Watou S, Tada C, Yamanaka Y, Miyata T, Oka M, Seino Y.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):82-9. PubMed ID: 9920066
    [Abstract] [Full Text] [Related]

  • 49. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial.
    Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO, Vance ML.
    J Clin Endocrinol Metab; 2004 May; 89(5):2048-56. PubMed ID: 15126520
    [Abstract] [Full Text] [Related]

  • 50. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
    Gill MS, Toogood AA, Jones J, Clayton PE, Shalet SM.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
    [Abstract] [Full Text] [Related]

  • 51. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
    Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wüster C.
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
    [Abstract] [Full Text] [Related]

  • 52. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults.
    Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB.
    Eur J Endocrinol; 2005 Jan; 152(1):67-75. PubMed ID: 15762189
    [Abstract] [Full Text] [Related]

  • 53. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G.
    Horm Res; 2005 Jan; 64(2):68-76. PubMed ID: 16113581
    [Abstract] [Full Text] [Related]

  • 54. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
    Verhelst J, Kendall-Taylor P, Erfurth EM, Price DA, Geffner M, Koltowska-Häggström M, Jönsson PJ, Wilton P, Abs R.
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
    [Abstract] [Full Text] [Related]

  • 55. Use of the ligand immunofunctional assay for human insulin-like growth factor ((IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and igf-i bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics.
    Lassarre C, Duron F, Binoux M.
    J Clin Endocrinol Metab; 2001 May; 86(5):1942-52. PubMed ID: 11344189
    [Abstract] [Full Text] [Related]

  • 56. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults.
    Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S, Severi F.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1324-8. PubMed ID: 10199773
    [Abstract] [Full Text] [Related]

  • 57. Growth hormone (GH) enhances anaerobic capacity: impact on physical function and quality of life in adults with GH deficiency.
    Chikani V, Cuneo RC, Hickman I, Ho KK.
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):660-8. PubMed ID: 27346880
    [Abstract] [Full Text] [Related]

  • 58. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
    Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM, Klibanski A.
    J Clin Endocrinol Metab; 2010 Feb; 95(2):567-77. PubMed ID: 20061426
    [Abstract] [Full Text] [Related]

  • 59. Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency.
    Aimaretti G, Fanciulli G, Bellone S, Maccario M, Arvat E, Delitala G, Camanni F, Ghigo E.
    Eur J Endocrinol; 2001 Sep; 145(3):267-72. PubMed ID: 11517006
    [Abstract] [Full Text] [Related]

  • 60. Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency.
    Kołtowska-Häggström M, Geffner ME, Jönsson P, Monson JP, Abs R, Hána V, Höybye C, Wollmann HA.
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2646-54. PubMed ID: 20335451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.